



FINANCIAL TEAR SHEET

Corporate Profile


Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce's technology also looks to match and deliver the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as the knowledge acquired from Jounce's Translational Science Platform, to create a sustainable pipeline that makes a difference in the lives of cancer patients.

Stock Information

JNCE (COMMON STOCK)

Exchange	NASDAQ GS (US Dollar)
Price	\$4.40
Change (%)	▼ 0.06 (1.35%)
Volume	328,815
52 Week Low	\$4.03
Market Cap	\$145,519,221
Rolling EPS	-0.96
PE Ratio	0
Shares Outstanding	32,627,628

Data as of 11/13/18 4:00 p.m. ET



Recent Headlines & Events

11/13/18 - 6:30 a.m.

Jounce Therapeutics Reports Third Quarter 2018 Financial Results

11/10/18 - 12:20 p.m.

Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

11/06/18 - 8:00 a.m.

Jounce Therapeutics to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 13, 2018

DATE	TITLE
11/13/18 8:00 a.m. ET	Q3 2018 Jounce Therapeutics, Inc. Earnings Conference Call

SEC Filings

FILING DATE	FORM
11/13/18	10-Q
11/13/18	8-K
11/09/18	8-K
09/07/18	4

Data provided by NASDAQ. Stock information is delayed a minimum of 15 minutes.